Bonfils Blood Center will begin production of Intercept® Platelets (pathogen-reduced) on July 25, 2016. The FDA approved Intercept® platelets in 2015, and they have been in use in Europe for over 10 years. Pathogen Reduction Technology (PRT) uses psoralen and exposure to UVA light to denature DNA and RNA, which prevents replication of white blood cells and all pathogens, except prions.

PRT platelets eliminate the need for irradiation or CMV-negative products. PRT platelets are FDA-approved to avoid TA-GVHD, and should not be irradiated. The platelet bags are larger and have a slightly different shape. The product will indicate “Psoralen-Treated” and will NOT have an irradiation indicator or state “Irradiated” on the label. Clinical use and indications are the same as current platelets, so there will be no changes in Epic on the clinical side with regard to ordering or documenting transfusions.

Click here for an information sheet on this product.

Please call Dr. Mary Berg at 720-848-4402 if you have any questions or visit our website at https://www.uchealth.org/professionals/Pages/Clinical-Laboratory.aspx for additional information.

Issued 07/15/2016